FCMI
Foresite Capital Management II Portfolio holdings
AUM
$29.2M
This Quarter Return
-18.23%
1 Year Return
+44.84%
3 Year Return
-66.21%
5 Year Return
-37.37%
10 Year Return
–
AUM
$428M
AUM Growth
+$428M
(-29%)
Cap. Flow
-$60.6M
Cap. Flow
% of AUM
-14.15%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
–
Reduced
5
Closed
–
Top Buys
| 1 |
Regenxbio
RGNX
|
$1.54M |
Top Sells
| 1 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$19.2M |
| 2 |
10x Genomics
TXG
|
$15.6M |
| 3 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$13.8M |
| 4 |
Insmed
INSM
|
$10.3M |
| 5 |
EPZM
Epizyme, Inc
EPZM
|
$3.28M |
Sector Composition
| 1 | Healthcare | 99.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
10x Genomics
TXG
$1.74B
| $411M | 95.85% |
6,587,253
-250,000
| -4% | -$15.6M |
|
|
EPZM
2
DELISTED
Epizyme, Inc
EPZM
| $5.89M | 1.38% |
379,981
-211,323
| -36% | -$3.28M |
|
|
3
Insmed
INSM
$28.8B
| $3.79M | 0.89% |
236,547
-643,469
| -73% | -$10.3M |
|
|
AERI
4
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $3.43M | 0.8% |
253,698
-1,419,016
| -85% | -$19.2M |
|
|
XLRN
5
DELISTED
Acceleron Pharma Inc.
XLRN
| $3.13M | 0.73% |
34,784
-153,818
| -82% | -$13.8M |
|
|
6
Regenxbio
RGNX
$451M
| $1.54M | 0.36% |
+47,443
| New | +$1.54M |
|